What SQZ Biotechnologies Co's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Capasso Richard | See Remarks | Aug 15 | Open-market sale · S | −1,183 | $3.33 | −$3.93K | 0 |
| Sharei Armon | President and CEO | Jun 30 | Grant / award · A | +2,436 | $2.70 | +$6.58K | 287,884 |
| Capasso Richard | See Remarks | Jun 30 | Grant / award · A | +1,183 | $2.70 | +$3.2K | 1,183 |
| Knopf Lawrence J | General Counsel | Jun 30 | Grant / award · A | +1,484 | $2.70 | +$4.01K | 1,938 |
| Jensen Klavs F. | Director | May 25 | Open-market buy · P | +14,326 | $3.52 | +$50.4K | 353,309 |
| Sharei Armon | President and CEO | Jan 12 | Exercise / conversion · M | +13,000 | $1.81 | +$23.5K | 285,448 |
| Sharei Armon | President and CEO | Dec 31 | Grant / award · A | +1,686 | $7.59 | +$12.8K | 272,448 |
| Knopf Lawrence J | General Counsel | Dec 31 | Grant / award · A | +454 | $7.59 | +$3.45K | 454 |
| Sharei Armon | President and CEO | Dec 22 | Exercise / conversion · M | +11,049 | $1.81 | +$20K | 270,762 |
| Schulman Amy W | Director | Dec 22 | Exercise / conversion · M | +6,581 | $4.59 | +$30.2K | 214,814 |
| Schulman Amy W | Director | Dec 22 | Exercise / conversion · M | +7,458 | $4.59 | +$34.2K | 208,233 |
| Schulman Amy W | Director | Dec 22 | Exercise / conversion · M | +10,091 | $2.02 | +$20.4K | 200,775 |
| Schulman Amy W | Director | Dec 13 | Open-market buy · P | +1,850 | $10.94 | +$20.2K | 1,850 |
| Schulman Amy W | Director | Dec 13 | Open-market buy · P | +1,850 | $10.88 | +$20.1K | 1,850 |
| Sharei Armon | President and CEO | Feb 27 | Exercise / conversion · M | +8,000 | $1.81 | +$14.5K | 259,713 |
| Sharei Armon | President and CEO | Jan 08 | Exercise / conversion · M | +2,500 | $1.81 | +$4.53K | 251,713 |
| Polaris Management Co. VII, L.l.c. | 10% owner | Nov 03 | Open-market buy · P | +233,654 | $16.00 | +$3.74M | 2,549,306 |
| Polaris Management Co. VII, L.l.c. | 10% owner | Nov 03 | Open-market buy · P | +16,346 | $16.00 | +$262K | 178,340 |
| Polaris Management Co. VII, L.l.c. | 10% owner | Nov 03 | Derivative Conversion · C | +2,315,652 | — | — | 2,315,652 |
| Polaris Management Co. VII, L.l.c. | 10% owner | Nov 03 | Derivative Conversion · C | +161,994 | — | — | 161,994 |
Loading...